These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 27457374)
1. Tocilizumab and mesenteric arterial thrombosis: drug-drug interaction with anticoagulants metabolized by CYP 450 and/or by P-glycoprotein. Clarivet B; Robin P; Pers YM; Ferreira R; Lebrun J; Jorgensen C; Hillaire-Buys D; Brés V; Faillie JL Eur J Clin Pharmacol; 2016 Nov; 72(11):1413-1414. PubMed ID: 27457374 [No Abstract] [Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation? Hellwig T; Gulseth M Ann Pharmacother; 2013 Nov; 47(11):1478-87. PubMed ID: 24259602 [TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis. Zhang X; Peck R Expert Rev Clin Pharmacol; 2011 Sep; 4(5):539-58. PubMed ID: 22114882 [TBL] [Abstract][Full Text] [Related]
4. [New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)]. Nasonov EL Ter Arkh; 2010; 82(5):64-71. PubMed ID: 20597275 [TBL] [Abstract][Full Text] [Related]
5. Onset of inflammatory eye disease under tocilizumab treatment for rheumatologic conditions: a paradoxical effect? Wendling D; Dernis E; Prati C; Frisch E; Delbosc B J Rheumatol; 2011 Oct; 38(10):2284. PubMed ID: 21965707 [No Abstract] [Full Text] [Related]
6. Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach. Gibiansky L; Frey N J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):5-16. PubMed ID: 22101760 [TBL] [Abstract][Full Text] [Related]
7. [Immunosuppression may mask severe infection. Septic arthritis in tocilizumab treatment yielded only modest acute-phase reaction]. Ljung L; Smeds J; Persson G; Jirlén L; Toolanen G Lakartidningen; 2012 Sep 19-26; 109(38):1678-9. PubMed ID: 23094399 [No Abstract] [Full Text] [Related]
8. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Genovese MC; McKay JD; Nasonov EL; Mysler EF; da Silva NA; Alecock E; Woodworth T; Gomez-Reino JJ Arthritis Rheum; 2008 Oct; 58(10):2968-80. PubMed ID: 18821691 [TBL] [Abstract][Full Text] [Related]
9. Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implications for molecular targeted therapy. Nishina N; Kikuchi J; Hashizume M; Yoshimoto K; Kameda H; Takeuchi T Ann Rheum Dis; 2014 May; 73(5):945-7. PubMed ID: 24336338 [No Abstract] [Full Text] [Related]
10. Interleukin-6 and cytochrome-P450, reason for concern? Kim S; Östör AJ; Nisar MK Rheumatol Int; 2012 Sep; 32(9):2601-4. PubMed ID: 22451032 [TBL] [Abstract][Full Text] [Related]
11. A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis. Protogerou AD; Zampeli E; Fragiadaki K; Stamatelopoulos K; Papamichael C; Sfikakis PP Atherosclerosis; 2011 Dec; 219(2):734-6. PubMed ID: 21968316 [TBL] [Abstract][Full Text] [Related]
13. Idarucizumab for dabigatran reversal in patients with atrial fibrillation undergoing emergency surgery for acute aortic syndrome. Mazur P; Darocha T; Filip G; Grudzień G; Drwiła R; Kapelak B Pol Arch Med Wewn; 2016 Jul; 126(7-8):579-81. PubMed ID: 27452811 [No Abstract] [Full Text] [Related]
14. Interleukin 6 as therapeutic target in athero-/arteriosclerosis--small steps towards a new treatment paradigm in cardiovascular disease? Henry RM Atherosclerosis; 2011 Dec; 219(2):390-1. PubMed ID: 21840523 [No Abstract] [Full Text] [Related]